Document:

Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant customarily and actually treats as private and confidential.
​

Exhibit 10.24
FOURTH AMENDMENT TO
PROJECT AGREEMENT
(DETAILING – FIELD TEAM)
​
This Fourth Amendment (the “Amendment”) entered into as of the last date of signature herein and made effective as of September 1, 2021 (the “Amendment Effective Date”) is made by and between Syneos Health Commercial Services, LLC, f/k/a inVentiv Commercial Services LLC, with an office at 500 Atrium Drive, Somerset, N.J. 08873 (“Syneos Health”) and Agile Therapeutics, Inc. with an office located at 500 College Road East, Suite 310, Princeton, New Jersey 08540 (the “Client”).  Syneos Health and Client may each be referred to herein as a “Party” and, collectively, as the “Parties.”
​
W I T N E S S E T H:
​
WHEREAS, Syneos Health and Client are parties to a Project Agreement (Detailing – Field Team) made as of April 30, 2020, First Amendment to Project Agreement (Detailing – Field Team) dated June 1, 2020, Second Amendment to Project Agreement (Detailing – Field Team) dated January 1, 2021 and Third Amendment to Project Agreement (Detailing – Field Team) dated July 1, 2021 (collectively, the “Agreement”); and
​
WHEREAS, Syneos Health and Client desire to amend the Agreement as set forth herein.
​
NOW THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, it is agreed as follows: 
​
1.Except as provided in this Amendment, the terms and conditions set forth in the Agreement shall remain unaffected by execution of this Amendment.  To the extent any provisions or terms set forth in this Amendment conflict with the terms set forth in the Agreement, the terms set forth in this Amendment shall govern and control.  Terms not otherwise defined herein, shall have the meanings set forth in the Agreement.
​
2.The Amended and Restated Exhibit A, the “Project Team” as defined is hereby amended to include [***].  Also, the table after the 2nd paragraph is hereby deleted in its entirety and replaced with the below table.
​
​
	Position
	Headcount

	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

​

​

The Amended and Restated Exhibit F, “Compensation – Fixed Fees, Variable Fees and Pass-through Costs,” is amended as follows:
​
		(a)	The table in Section I, “Fixed Fees,” is hereby deleted in its entirety and replaced with the below table.

​
	Position
	Headcount

	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

​
		(b)	Section I(b), “Fixed Monthly Fee,” paragraph (i) is hereby amended and restated as follows:

​
		(i)	Commencing on the [***] Date, Client shall pay Syneos Health [***] as follows:

​
	[***]
	[***]

	[***]
	[***]

​
[***]
3.This Amendment may be executed simultaneously in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.  Execution and delivery of this Amendment by exchange of facsimile copies or via pdf file bearing the facsimile signature of a party hereto shall constitute a valid and binding execution and delivery of this Amendment by such party.  Such facsimile copies and/or pdf versions shall constitute enforceable original documents.
​
4.The terms of this Amendment are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and may not be contradicted by evidence of any prior or contemporaneous agreement.  The Parties further intend that this 
​

​

​

Amendment constitute the complete and exclusive statement of its terms and shall supersede any prior agreement with respect to the subject matter hereof.
​
WHEREFORE, the parties hereto have caused this Amendment to be executed by their duly authorized representatives.
​
	AGILE THERAPEUTICS, INC.
	SYNEOS HEALTH COMMERCIAL SERVICES, LLC

​
By: _/s/ Al Altomari__________________By: _/s/ Todd Tomasoski
​
Name: Name: Todd Tomasoski
​
Title:Title: Vice President, Global Deal Management
​
Date: Date: Dec 28, 2021

​Exhibit 4.1
DESCRIPTION OF NORTHEAST COMMUNITY BANCORP, INC.’S COMMON STOCK
REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
General
NorthEast Community Bancorp, Inc. (the “Company”) is incorporated in the State of Maryland. The rights of our shareholders are generally covered by Maryland law and our articles of incorporation and bylaws (each as amended and in effect on the date hereof). The terms of our common stock are therefore subject to Maryland law, including the Maryland General Corporation Law, and the common and constitutional law of Maryland.
This exhibit describes the general terms of our common stock. This is a summary and does not purport to be complete. Our articles of incorporation and bylaws as they exist on the date of this Annual Report on Form 10-K are incorporated by reference or filed as an exhibit to the Annual Report on Form 10-K of which this exhibit is a part, and amendments or restatements of each will be filed with the Securities and Exchange Commission (the “SEC”) in future periodic or current reports in accordance with the rules of the SEC. You are encouraged to read these documents.
For more detailed information about the rights of our common stock, you should refer to our article of incorporation and bylaws and the applicable provisions of Maryland law, including the Maryland General Corporation Law, for additional information.
Authorized Shares
The Company is authorized to issue 75,000,000 shares of common stock, having a par value of  $0.01 per share, and 25,000,000 shares of preferred stock, having a par value of $0.01 per share. Each share of the Company’s common stock has the same relative rights as, and is identical in all respects with, each other share of common stock.
Exchange Listing
The Company’s common stock is currently listed on the Nasdaq Capital Market under the symbol “NECB.”
Dividends
The Company can pay dividends if, as and when declared by its board of directors. The payment of dividends by the Company is limited by law and applicable regulation. The holders of the Company’s common stock are entitled to receive and share equally in dividends declared by the board of directors of the Company. If the Company issues preferred stock, the holders of the preferred stock may have a priority over the holders of the common stock with respect to dividends.
Voting Rights
The holders of the Company’s common stock possess exclusive voting rights in the Company. The holders of the Company’s common stock elect the Company’s board of directors and act on other matters as are required to be presented to them under Maryland law or as are otherwise presented to them by the board of directors.
Each holder of common stock is generally entitled to one vote per share. However, the Company’s articles of incorporation provide that record holders of the Company’s common stock who beneficially own, either directly or indirectly, in excess of 10% of the Company’s outstanding shares are generally not entitled to any vote with respect to those shares held in excess of the 10% limit. A majority of the Company’s disinterested directors may approve a stockholder acquiring and voting in excess of 10% of the Company’s outstanding shares before the stockholder acquires any shares in excess of the 10% limit.

If the Company issues preferred stock, holders of the Company’s preferred stock may also possess voting rights.
Liquidation
If there is any liquidation, dissolution or winding up of NorthEast Community Bank, the Company, as the sole holder of NorthEast Community Bank’s capital stock, would be entitled to receive all of NorthEast Community Bank’s assets available for distribution after payment or provision for payment of all debts and liabilities of NorthEast Community Bank, including all deposit accounts and accrued interest.
Upon liquidation, dissolution or winding up of the Company, the holders of its common stock would be entitled to receive all of the assets of the Company available for distribution after payment or provision for payment of all its debts and liabilities.
If  the Company issues preferred stock, the preferred stock holders may have a priority over the holders of the common stock upon liquidation or dissolution of the Company.
Preemptive Rights
Holders of the Company’s common stock are not be entitled to preemptive rights with respect to any shares that may be issued.
Redemption; Sinking Funds; Conversion
The Company’s common stock is not subject to any mandatory redemption, sinking fund or other similar provisions. Holders of the Company’s common stock have no right to require redemption or repurchase of any of their shares. The Company’s common stock has no conversion rights.Exhibit 4.19

 

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

The following description
sets forth certain material terms and provisions of the securities of OpGen Inc. (the “Company,” “we,” “us”
and “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
This description also summarizes relevant provisions of Delaware General Corporation Law (the “DGCL”). The following summary
does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the applicable provisions of the
DGCL and our certificate of incorporation and our by-laws, copies of which are incorporated by reference as an exhibit to the Annual Report
on Form 10-K of which this Exhibit 4.13 is a part. We encourage you to read our certificate of incorporation, our by-laws and the applicable
provisions of the DGCL for additional information.

Our common stock, par value
$0.01 per share, trading symbol OPGN is registered under Section 12(b) of the Exchange Act.

Authorized Capital Stock

As of December 31, 2021,
our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred
stock, par value $0.01 per  share, of which 10,000,000 shares are available for future issuance. As of March 25, 2022, 46,557,750
shares of our common stock are issued and outstanding.

Common Stock

The holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock
do not have any cumulative voting rights. The Board of Directors are elected to a one year term; the Company does not have a staggered
board. Holders of our common stock are entitled to receive ratably any dividends declared by the Board of Directors out of funds legally
available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive
rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

In the event of our liquidation,
dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all
debts and other liabilities and any liquidation preference of any outstanding preferred stock.

Anti-Takeover Effects of Our Certificate of Incorporation, Bylaws
and Delaware Law

Our certificate of incorporation
and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control
of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board
of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.

Meetings of Stockholders

Our certificate of incorporation
and bylaws provide that only the Chair of the Board, the Chief Executive Officer or a majority of the members of our board of directors
then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be
considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting
of stockholders to those matters properly brought before the meeting.

Advance Notice Requirements

Our bylaws establish advance
notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business
to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given
in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be
received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual
meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders’ notices. These requirements
may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.

    	  

    	 

    

Amendment to Certificate of Incorporation and Bylaws

Any amendment of our certificate
of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation,
must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment. Our bylaws may be amended by the
affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended
by the affirmative vote of at least 66 2/3% of the outstanding shares entitled to vote on the amendment, or, if our board of directors
recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to
vote on the amendment, in each case voting together as a single class.

Undesignated Preferred Stock

Our board of directors
has the authority, without further action by our stockholders, to issue from time to time 10,000,000 shares of preferred stock in one
or more series. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an
attempt to  obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due
exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests
of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or
more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder
or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights
and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount
of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights
and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control
of us.

Exclusive Jurisdiction for Certain Actions

Our certificate of incorporation
provides that, once our common stock is a “covered security,” unless we consent in writing to the selection of an alternative
forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding
brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other
employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation
Law, our certificate of incorporation or our bylaws, or (iv) any action asserting a claim against us governed by the internal affairs
doctrine. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the
types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers.
The enforceability of similar exclusive forum provisions in other companies’ certificates of incorporation has been challenged in
legal proceedings, and it is possible that a court could rule that this provision in our certificate of incorporation is inapplicable
or unenforceable. In addition, this exclusive forum provision is intended to apply to claims arising under Delaware state law and would
not apply to claims brought pursuant to the Securities Act or the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction. To the extent the provision could be construed to apply to such claims, there is uncertainty as to
whether a court would enforce the provision in such respect, and our stockholders will not be deemed to have waived compliance with federal
securities laws and the rules and regulations thereunder. 

    	  

    	 

    

Section 203 of the Delaware General Corporation Law

We are subject to the provisions of Section
203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a
“business combination” with an “interested stockholder” for a three-year period following the time that this stockholder
becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination
between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:

	 	·	before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

 

	 	·	upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or

 

	 	·	at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

Section 203 defines a business combination to include:

	 	·	any merger or consolidation involving the corporation and the interested stockholder;

 

	 	·	any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

 

	 	·	subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

	 	·	subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and

 

	 	·	the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

 

In general, Section 203 defines an interested stockholder
as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated
with or controlling or controlled by the entity or person.

 

Listing

Our common stock is listed on the Nasdaq Capital
Market under the symbol “OPGN”.

Transfer Agent and Registrar

The transfer agent and registrar for our common
stock is Philadelphia Stock Transfer, Inc. The transfer agent’s address is 2320 Haverford Rd., Suite 230, Ardmore, PA 19003.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]